ALX ONCOLOGY HOLDINGS INC Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Alx Oncology Holdings Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q3 2024.
  • Alx Oncology Holdings Inc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$30.7M, a 39.8% increase year-over-year.
  • Alx Oncology Holdings Inc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$151M, a 3.5% decline year-over-year.
  • Alx Oncology Holdings Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$161M, a 30.2% decline from 2022.
  • Alx Oncology Holdings Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$123M, a 47.9% decline from 2021.
  • Alx Oncology Holdings Inc annual Net Income (Loss) Attributable to Parent for 2021 was -$83.5M, a 82.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$151M -$30.7M +$20.3M +39.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$171M -$39.4M -$5.24M -15.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$166M -$35.6M -$5.4M -17.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 -$161M -$45.5M -$14.8M -48.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$146M -$51M -$15.7M -44.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$130M -$34.2M -$1.24M -3.76% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$129M -$30.2M -$5.65M -23% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$123M -$30.7M -$2.27M -7.99% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 -$121M -$35.3M -$10.8M -43.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$110M -$32.9M -$16.6M -102% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$93.8M -$24.5M -$10.3M -73% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$83.5M -$28.4M -$9.66M -51.5% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-07
Q3 2021 -$73.8M -$24.6M -$14.4M -141% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$59.4M -$16.3M -$4.94M -43.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$54.5M -$14.2M -$8.73M -160% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$45.7M -$18.8M -$11M -142% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-09
Q3 2020 -$34.7M -$10.2M -$7.14M -234% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$27.6M -$11.3M -$7.13M -170% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$20.5M -$5.45M -$1.22M -28.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-08-12
Q4 2019 -$19.2M -$7.76M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 -$3.04M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$4.2M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-12
Q1 2019 -$4.24M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.